These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35150809)

  • 1. DAB2IP suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination in colon cancer.
    Feng S; Huang Q; Deng J; Jia W; Gong J; Xie D; Shen J; Liu L
    Cancer Lett; 2022 Apr; 532():215588. PubMed ID: 35150809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer.
    Miller AL; Perurena N; Gardner A; Hinoue T; Loi P; Laird PW; Cichowski K
    Cancer Res; 2023 Jun; 83(11):1800-1814. PubMed ID: 36939385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells.
    Duan Y; Yin X; Lai X; Liu C; Nie W; Li D; Xie Z; Li Z; Meng F
    Technol Cancer Res Treat; 2020; 19():1533033819895494. PubMed ID: 32336215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.
    Tsai YS; Lai CL; Lai CH; Chang KH; Wu K; Tseng SF; Fazli L; Gleave M; Xiao G; Gandee L; Sharifi N; Moro L; Tzai TS; Hsieh JT
    Oncotarget; 2014 Aug; 5(15):6425-36. PubMed ID: 25115390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation.
    Yang G; Gong Y; Wang Q; Wang L; Zhang X
    Oncogene; 2017 Feb; 36(8):1023-1037. PubMed ID: 27524417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smurf1 regulation of DAB2IP controls cell proliferation and migration.
    Li X; Dai X; Wan L; Inuzuka H; Sun L; North BJ
    Oncotarget; 2016 May; 7(18):26057-69. PubMed ID: 27036023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma.
    Zhang X; Li N; Li X; Zhao W; Qiao Y; Liang L; Ding Y
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1117-25. PubMed ID: 22168621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma.
    Guo W; Yan L; Yang L; Liu X; E Q; Gao P; Ye X; Liu W; Zuo J
    PLoS One; 2014; 9(1):e85766. PubMed ID: 24465691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation.
    Zhou Y; Yang Z; Zhang H; Li H; Zhang M; Wang H; Zhang M; Qiu P; Zhang R; Liu J
    Biochim Biophys Acta Mol Basis Dis; 2022 Apr; 1868(4):166353. PubMed ID: 35063646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
    Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras association domain family 1 isoform A suppresses colonic tumor cell growth through p21
    Oh SJ; Lee MG; Moon JR; Lee CK; Chi SG; Kim HJ
    J Gastroenterol Hepatol; 2019 May; 34(5):890-898. PubMed ID: 30226276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer.
    Bellazzo A; Di Minin G; Collavin L
    Cell Death Differ; 2017 Jan; 24(1):15-25. PubMed ID: 27858941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAB2IP in cancer.
    Liu L; Xu C; Hsieh JT; Gong J; Xie D
    Oncotarget; 2016 Jan; 7(4):3766-76. PubMed ID: 26658103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer.
    Zhang M; Peng Y; Yang Z; Zhang H; Xu C; Liu L; Zhao Q; Wu J; Wang H; Liu J
    BMC Cancer; 2022 May; 22(1):561. PubMed ID: 35590292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.
    Di Minin G; Bellazzo A; Dal Ferro M; Chiaruttini G; Nuzzo S; Bicciato S; Piazza S; Rami D; Bulla R; Sommaggio R; Rosato A; Del Sal G; Collavin L
    Mol Cell; 2014 Dec; 56(5):617-29. PubMed ID: 25454946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAB2IP inhibits glucose uptake by modulating HIF-1α ubiquitination under hypoxia in breast cancer.
    Dong H; Jia W; Meng W; Zhang R; Qi Z; Chen Z; Xie S; Min J; Liu L; Shen J
    Oncogenesis; 2024 Jun; 13(1):20. PubMed ID: 38862467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
    Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP.
    Valentino E; Bellazzo A; Di Minin G; Sicari D; Apollonio M; Scognamiglio G; Di Bonito M; Botti G; Del Sal G; Collavin L
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7623-7628. PubMed ID: 28667123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.
    Zhou J; Ning Z; Wang B; Yun EJ; Zhang T; Pong RC; Fazli L; Gleave M; Zeng J; Fan J; Wang X; Li L; Hsieh JT; He D; Wu K
    Cell Death Dis; 2015 Oct; 6(10):e1955. PubMed ID: 26512963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.
    Fan X; Wang Y; Fan J; Chen R
    J Cell Biochem; 2019 Jun; 120(6):10643-10651. PubMed ID: 30672020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.